Evidence map›Paper›PMID 28025059›Full record

ArticleJournal of hepatology2017

MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.

Heng Wu, Tianpeng Zhang, Fei Pan, Clifford J Steer, Zhuoyu Li, Xin Chen, Guisheng Song

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Epigenetic regulation in a high-sugar environment (Review).International journal of molecular medicine · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Heng WuDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Tianpeng ZhangDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Fei PanDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Clifford J SteerDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA.
Zhuoyu LiInstitute of Biotechnology, Shanxi University, Taiyuan City 030006, China.
Xin ChenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
Guisheng SongDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: gsong@umn.edu.
University of Minnesota Medical Center · USShanxi University · CNUniversity of California, San Francisco · USUniversity of Minnesota · US

Funding

Molecular Genetics of Liver CancersR01CA136606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2009 to 2016
$2.6M
miR-378/378* promotes hepatic lipid accumulation and progression of NAFLD to NASHR01DK102601 · NIDDK · UNIVERSITY OF MINNESOTA · PI SONG, GUISHENG · 2014 to 2018
$2.1M
NCI NIH HHS R01 CA136606NIDDK NIH HHS R01 DK102601
6 · The paper itself

Abstract

BACKGROUND &

aimsThe paradox of selective hepatic insulin resistance, wherein the insulin-resistant liver fails to suppress glucose production but continues to produce lipids, has been central to the pathophysiology of hepatosteatosis and hyperglycemia. Our study was designed to investigate the mechanism(s) by which microRNA-206 alleviates the pathogenesis of hepatosteatosis and hyperglycemia.

methodsDietary obese mice induced by a high fat diet were used to study the role of microRNA-206 in the pathogenesis of hepatosteatosis and hyperglycemia. A mini-circle vector was used to deliver microRNA-206 into the livers of mice.

resultsLipid accumulation impaired biogenesis of microRNA-206 in fatty livers of dietary obese mice and human hepatocytes (p<0.01). Delivery of microRNA-206 into the livers of dietary obese mice resulted in the strong therapeutic effects on hepatosteatosis and hyperglycemia. Mechanistically, miR-206 interacted with the 3' untranslated region of PTPN1 (protein tyrosine phosphatase, non-receptor type 1) and induced its degradation. By inhibiting PTPN1 expression, microRNA-206 facilitated insulin signaling by promoting phosphorylation of INSR (insulin receptor) and impaired hepatic lipogenesis by inhibiting Srebp1c transcription. By simultaneously modulating lipogenesis and insulin signaling, microRNA-206 reduced lipid (p=0.006) and glucose (p=0.018) production in human hepatocytes and livers of dietary obese mice (p<0.001 and p<0.01 respectively). Re-introduction of Ptpn1 into livers offset the inhibitory effects of microRNA-206, indicating that PTPN1 mediates the inhibitory effects of microRNA-206 on both hepatosteatosis and hyperglycemia.

conclusionsMicroRNA-206 is a potent inhibitor of lipid and glucose production by simultaneously facilitating insulin signaling and impairing hepatic lipogenesis. Our findings potentially provide a novel therapeutic agent for both hepatosteatosis and hyperglycemia. LAY SUMMARY: The epidemic of obesity is causing a sharp rise in the incidence of insulin resistance and its major complications, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). However, there are no effective treatments because the mechanisms underlying both disorders are not well described. We identified microRNA-206 as a novel and effective inhibitor for both glucose and lipid production in liver and potentially provide a unique therapeutic drug for both hepatosteatosis and hyperglycemia.

Indexed as

3' Untranslated RegionsAnimalsDiet, High-FatHepatocytesHep G2 CellsHumansHyperglycemiaInsulinInsulin ResistanceLipogenesisLiverMaleMiceMice, Inbred C57BLMicroRNAsNon-alcoholic Fatty Liver Disease3' Untranslated RegionsInsulinMicroRNAsMIRN206 microRNA, humanMirn206 microRNA, mouseProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanPtpn1 protein, mouseSrebf1 protein, mouseSterol Regulatory Element Binding Protein 1Diet, high-fatHyperglycemiaInsulin signalingLipogenesisMicroRNAsNAFLDPhosphorylation

Identifiers

PMID28025059
PMCPMC5568011
OpenAlexW2566219506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.